新闻资讯
科思
/
/
/
Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

  • 分类:学术论文
  • 作者:
  • 来源:
  • 发布时间:2016-08-12 09:23
  • 访问量:

【概要描述】 Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement.

Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

【概要描述】 Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement.

  • 分类:学术论文
  • 作者:
  • 来源:
  • 发布时间:2016-08-12 09:23
  • 访问量:
详情

  Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement. Moreover, DES PCI is affected by vasomotion impairment. In ACS a high thrombus burden and vasospasm lead to a higher risk of acute and late acquired stent malapposition than in stable patients. This increases the risk of acute, late and very late stent thrombosis. In this challenging clinical setting, the implantation of bioresorbable vascular scaffolds (BVS) could represent an appealing therapeutic option. Temporary vessel scaffolding has proved to have several advantages over metallic stent delivery, such as framework reabsorption, late lumen enlargement, side branch patency, and recovery of physiological reactivity to vasoactive stimuli. In the thrombotic environment of ACS, BVS implantation has the benefit of capping the thrombus and the vulnerable plaque. Bioresorbable vascular scaffolds also seems to reduce the incidence of angina during follow-up. Acute coronary syndromes patients may therefore benefit more from temporary polymeric caging than from permanent stent platform implantation. The aim of this review is to update the available knowledge concerning the use of BVS in ACS patients, by analyzing the potential pitfalls in this challenging clinical setting and presenting tricks to overcome these limitations.

中国生物材料学会材料生物力学分会换届大会圆满召开
2022 12-08

中国生物材料学会材料生物力学分会换届大会圆满召开

精准植入 完美心舒——冠脉支架定位系统
2022 11-27

精准植入 完美心舒——冠脉支架定位系统

北京阿迈特与北京航空航天大学联合参与生物医疗器械国家急需高层次人才培养专项
2022 11-26

北京阿迈特与北京航空航天大学联合参与生物医疗器械国家急需高层次人才培养专项

公司信息

北京阿迈特医疗器械有限公司

Beijing Advanced Medical Technologies,Ltd.Inc.

联系我们

地址:北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话:010-6297-7955             邮箱:amt@ametcorp.com

联系我们

地址:北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话:010-6297-7955             

邮箱:amt@ametcorp.com